Ann: SOLVE-CRT trial data accepted into HRS conference, page-2

Another excellent development for EBR:
"We are honoured to be accepted into such a prestigious conference and to have our results featured in the Late Breaking Clinical Trials session."
"These sessions get the most recognition in the clinical community. A positive trial outcome, if achieved, would represent a significant milestone on our path towards achieving FDA and regulatory approvals, whereby we can commence our commercialisation strategy.”

Would EBR be seeking to present data on the SOLVE trial without confidence of its success? I wonder . . .